JP2023113641A5 - - Google Patents

Download PDF

Info

Publication number
JP2023113641A5
JP2023113641A5 JP2023077454A JP2023077454A JP2023113641A5 JP 2023113641 A5 JP2023113641 A5 JP 2023113641A5 JP 2023077454 A JP2023077454 A JP 2023077454A JP 2023077454 A JP2023077454 A JP 2023077454A JP 2023113641 A5 JP2023113641 A5 JP 2023113641A5
Authority
JP
Japan
Prior art keywords
methods
new products
manufacturing methods
manufacturing
methods substantially
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023077454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023113641A (ja
Filing date
Publication date
Priority claimed from PCT/US2018/052855 external-priority patent/WO2019067540A1/en
Application filed filed Critical
Publication of JP2023113641A publication Critical patent/JP2023113641A/ja
Publication of JP2023113641A5 publication Critical patent/JP2023113641A5/ja
Pending legal-status Critical Current

Links

JP2023077454A 2017-09-27 2023-05-09 翻訳後修飾された完全ヒト抗VEGF Fabによる眼疾患の治療 Pending JP2023113641A (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201762564095P 2017-09-27 2017-09-27
US62/564,095 2017-09-27
US201762574657P 2017-10-19 2017-10-19
US62/574,657 2017-10-19
US201762579682P 2017-10-31 2017-10-31
US62/579,682 2017-10-31
US201862632812P 2018-02-20 2018-02-20
US62/632,812 2018-02-20
PCT/US2018/052855 WO2019067540A1 (en) 2017-09-27 2018-09-26 TREATMENT OF OCULAR DISEASES WITH A TOTALLY HUMAN POST-TRANSLATIONAL MODIFICATION ANTI-VEGF FAB
JP2020517843A JP7685833B2 (ja) 2017-09-27 2018-09-26 翻訳後修飾された完全ヒト抗VEGF Fabによる眼疾患の治療

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020517843A Division JP7685833B2 (ja) 2017-09-27 2018-09-26 翻訳後修飾された完全ヒト抗VEGF Fabによる眼疾患の治療

Publications (2)

Publication Number Publication Date
JP2023113641A JP2023113641A (ja) 2023-08-16
JP2023113641A5 true JP2023113641A5 (https=) 2025-05-15

Family

ID=65903176

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020517843A Active JP7685833B2 (ja) 2017-09-27 2018-09-26 翻訳後修飾された完全ヒト抗VEGF Fabによる眼疾患の治療
JP2023077454A Pending JP2023113641A (ja) 2017-09-27 2023-05-09 翻訳後修飾された完全ヒト抗VEGF Fabによる眼疾患の治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020517843A Active JP7685833B2 (ja) 2017-09-27 2018-09-26 翻訳後修飾された完全ヒト抗VEGF Fabによる眼疾患の治療

Country Status (9)

Country Link
US (3) US20200277364A1 (https=)
EP (1) EP3687464A4 (https=)
JP (2) JP7685833B2 (https=)
KR (2) KR20250040754A (https=)
AU (2) AU2018342094B2 (https=)
CA (1) CA3076905A1 (https=)
IL (1) IL273403A (https=)
SG (1) SG11202002396TA (https=)
WO (1) WO2019067540A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2916827B1 (en) 2012-11-08 2020-06-10 Clearside Biomedical Inc. Methods for the treatment of ocular disease in human subjects
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
JP7046828B2 (ja) 2016-04-15 2022-04-04 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 滲出型加齢性黄斑変性の治療のための組成物
MX2020006435A (es) 2017-12-19 2021-02-09 Akouos Inc Administracion de anticuerpos terapeuticos mediada por vector de virus adenoasociado (aav) en el oido interno.
US12558434B2 (en) 2018-02-20 2026-02-24 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
US20220133908A1 (en) * 2019-02-08 2022-05-05 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
EP4667578A3 (en) * 2019-04-03 2026-04-01 REGENXBIO Inc. Gene therapy for eye pathologies
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
CN110423281B (zh) * 2019-07-31 2021-04-30 成都金唯科生物科技有限公司 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物
WO2021041373A1 (en) 2019-08-26 2021-03-04 Regenxbio Inc. Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab
AU2020362119A1 (en) 2019-10-07 2022-05-26 Regenxbio Inc. Adeno-associated virus vector pharmaceutical composition and methods
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US20230201371A1 (en) * 2020-03-19 2023-06-29 Clearside Biomedical, Inc. Compositions and methods for treating ocular disorders
CN116234917A (zh) 2020-07-27 2023-06-06 安杰瑞姆生物科学公司 Dna分子组合物及其制备方法和使用方法
US20230372538A1 (en) * 2020-10-07 2023-11-23 Regenxbio Inc. Formulations for suprachoroidal administration such as formulations with aggregate formation
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
WO2022165313A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
EP4401836A1 (en) * 2021-09-18 2024-07-24 Skyline Therapeutics Limited Aav for the gene therapy of wet-amd
CN116925234B (zh) * 2022-04-02 2024-05-31 合肥星眸生物科技有限公司 一种编码抗vegf-a和ang-2双特异性抗体的aav载体
IL319873A (en) 2022-09-30 2025-05-01 Regenxbio Inc Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943153B1 (en) * 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US20070202186A1 (en) * 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
KR20140014405A (ko) * 2009-05-28 2014-02-06 글락소 그룹 리미티드 안구 질병을 치료하거나 예방하는데 사용되는 tnf-알파 길항제 및 vegf 길항제의 조합물
PE20120622A1 (es) * 2009-06-17 2012-05-26 Abbott Biotherapeutics Corp Anticuerpos anti-vegf y sus usos
EP2559443A1 (en) * 2011-08-16 2013-02-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject
TWI775096B (zh) * 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
JP2016531149A (ja) * 2013-09-11 2016-10-06 ニューロテック ユーエスエー, インコーポレイテッド カプセル化細胞療法カートリッジ
US10064752B2 (en) * 2014-09-11 2018-09-04 Orbit Biomedical Limited Motorized suprachoroidal injection of therapeutic agent
CN108778330A (zh) * 2016-01-08 2018-11-09 科尼尔赛德生物医学公司 用阿柏西普和其他生物制品治疗后眼部障碍的方法和装置
WO2017181021A1 (en) * 2016-04-15 2017-10-19 Regenxbio Inc. Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab
JP7046828B2 (ja) * 2016-04-15 2022-04-04 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 滲出型加齢性黄斑変性の治療のための組成物
US12558434B2 (en) * 2018-02-20 2026-02-24 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
US20230201371A1 (en) * 2020-03-19 2023-06-29 Clearside Biomedical, Inc. Compositions and methods for treating ocular disorders

Similar Documents

Publication Publication Date Title
JP2023113641A5 (https=)
JP2024156852A5 (https=)
JP2024133471A5 (https=)
JP2026012786A5 (https=)
JP2024037765A5 (https=)
JP2023113681A5 (https=)
JP2025023938A5 (https=)
JP2023164986A5 (https=)
JP2023153863A5 (https=)
JP2026048925A5 (https=)
JP2025106258A5 (https=)
JP2023134519A5 (https=)
JP2023103231A5 (https=)
JP2025118771A5 (https=)
JP2024156705A5 (https=)
JP2025038009A5 (https=)
JP2024088648A5 (https=)
JP2023139025A5 (https=)
JP2023154065A5 (https=)
JP2018100276A5 (https=)
JP2025143267A5 (https=)
JP2024160274A5 (https=)
JP2025124655A5 (https=)
JP2025041678A5 (https=)
JP2024038101A5 (https=)